Fig. 4
From: Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics
A schematic illustration of osteosarcoma cell internalization nanocarriers by active targeting. Various targeting ligand-modified nanocarriers initiate receptor-mediated endocytosis by binding to receptors on the surface of osteosarcoma cell. In addition to binding to osteosarcoma cell surface markers, nanocarriers can also exert anti-osteosarcoma activity by targeting moiety, such as targeting mitochondria or the nucleus